XML 56 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Taxes  
Schedule of provision for income taxes

Year Ended December 31, 

    

2023

    

2022

2021

Federal

$

31,084

$

10,011

$

6,487

State

 

11,884

 

9,573

 

2,852

Valuation allowance

 

1,575

 

(96,366)

 

(6,508)

$

44,543

$

(76,782)

$

2,831

Current

$

57,962

$

9,161

$

2,831

Deferred

 

(14,994)

 

10,423

 

6,508

Valuation allowance

 

1,575

 

(96,366)

 

(6,508)

Total

$

44,543

$

(76,782)

$

2,831

Schedule of reconciliation between statutory federal income tax rate and the Company's effective income tax rate

Year Ended December 31, 

2023

    

2022

2021

Federal income tax rate

21.0

%  

21.0

%

21.0

%

Stock-based compensation

(0.4)

(4.9)

(2.3)

State taxes

5.7

(14.1)

6.4

Credits

(2.1)

(4.8)

Other

0.9

(0.3)

(0.2)

Valuation allowance

0.6

(70.2)

(17.3)

Total

25.7

%  

(73.3)

%

7.6

%

Schedule of significant components of company's deferred tax assets and liabilities

    

As of December 31, 

2023

    

2022

Assets

    

Liabilities

Assets

    

Liabilities

Acquired in-process research and development

$

35,337

$

$

45,938

$

Net operating loss carryforward

 

45,917

 

 

6,370

 

Accrued compensation

 

19,915

 

 

11,551

 

Lease obligations, net

 

-

 

6

 

71

 

Fixed assets

 

173

 

 

115

 

Inventory

 

5,344

 

 

6,781

 

Accrued rebates

3,791

7,118

Research and development

38,799

8,802

Other

 

1,132

 

790

 

15

 

818

Total

$

150,408

 

796

$

86,761

 

818

Net deferred tax asset

$

149,612

$

$

85,943

$

Valuation allowance

$

(5,450)

$

$

$

Total

$

144,162

$

$

85,943

$

Schedule of change in valuation allowance for deferred tax assets

Year Ended December 31, 

    

2023

    

2022

2021

Valuation allowance at the beginning of the year

$

$

(96,366)

$

(102,874)

Decreases recorded as a benefit to income tax provision

 

 

96,366

 

6,508

Increases due to Zynerba Acquisition

(3,875)

Increases recorded to income tax provision

(1,575)

Valuation allowance at the end of the year

$

(5,450)

$

$

(96,366)